Inhibitor Therapeutics, Inc. (INTI)
About Inhibitor Therapeutics, Inc.
INHIBITOR THERAPTICS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$3.3M
- Total assets
- $2.5M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Inhibitor Therapeutics, Inc. (INTI) Stock Price
- Reported a net loss of $3.3M in FY2021.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inhibitor Therapeutics, Inc..
Write a review
News about Inhibitor Therapeutics, Inc.
News & sentiment via Polygon.io
Inhibitor Therapeutics, Inc.: frequently asked questions
Is Inhibitor Therapeutics, Inc. an American company?
Inhibitor Therapeutics, Inc. is a US-based company headquartered in Tampa, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Inhibitor Therapeutics, Inc. headquartered?
Inhibitor Therapeutics, Inc. is headquartered in Tampa, Florida, United States.
Is Inhibitor Therapeutics, Inc. publicly traded?
Yes — Inhibitor Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol INTI on the OTC.
What does Inhibitor Therapeutics, Inc. do?
Inhibitor Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
